Your session is about to expire
← Back to Search
ERC1671 for Gliosarcoma
Study Summary
This trial looks at a new treatment for glioblastoma and gliosarcoma (both brain cancer) that includes the drug ERC1671. It is compared to the standard treatment, which is just bevacizumab (a different drug).
- Gliosarcoma
- Glioblastoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are we looking for more participants in this clinical trial at the moment?
"This particular trial is not looking for new participants at the moment. It was originally posted on March 1st, 2014 but has since been updated on May 10th, 2022. There are currently 459 other trials recruiting patients with gliosarcoma and 1357 different trials seeking ERC1671 participants."
How many individuals are being administered lenalidomide in this test group?
"Although this study is not currently looking for patients, it may in the future. According to the latest update on clinicaltrials.gov, the trial was most recently edited on May 10th, 2022. 459 other trials for gliosarcoma and 1357 trials for ERC1671 are actively recruiting participants right now."
What is ERC1671's current standing with the FDA?
"There is limited data on ERC1671's safety, but none yet on its efficacy. Our team has given it a score of 2."
Is this the first time ERC1671 has been used in a clinical setting?
"ERC1671 was first trialled in 1997 at City of Hope Comprehensive Cancer Center. So far, 2688 rounds of clinical trials have completed. Currently, there are 1357 ongoing clinical trials with a large portion happening in Boston, Massachusetts."
What are the primary conditions that ERC1671 has been known to treat?
"ERC1671 is frequently used to treat lymphoma, but can also be effective in treating acute lymphoblastic leukemia (all), hypochloremic state, and electrolyte replacement therapy."
Share this study with friends
Copy Link
Messenger